Recent Updates
Recently added Catalysts
IDYA

IDEAYA Announces Development Candidate Nomination of a Potential First in Class Pol Theta Helicase Inhibitor in Collaboration with GSK

Tuesday, June 28, 2022 1 min read
Key Takeaway: IDEAYA Announces Development Candidate Nomination of a Potential First in Class Pol Theta Helicase Inhibitor in Collaboration with GSK

Full Press Release Details

IDEAYA Announces Development Candidate Nomination of a Potential First in Class Pol Theta Helicase Inhibitor in Collaboration with GSK.
Tags: IDYA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jun 28, 2022